Silence Therapeutics plc (SLN) is a clinical-stage biotechnology company dedicated to developing innovative medicines that use a technology called small interfering RNA (siRNA). Think of siRNA as a precise switch that can turn off specific genes that cause diseases. The company uses its special "mRNAi GOLD™ platform" to create these medicines, focusing on serious conditions in areas like heart disease, blood disorders, and rare diseases where current treatments aren't enough.

The Business Model (How They Make Money)

Silence Therapeutics primarily makes money through collaboration agreements with larger pharmaceutical companies. These collaborations involve sharing their technology and drug candidates, often receiving upfront payments, research funding, and potential milestone payments as their drug candidates advance through development stages.

For the full year ended December 31, 2025, Silence Therapeutics reported collaboration revenue of $0.6 million. This represented essentially all of their revenue for that year. This was a significant decrease from the previous year, mainly because a collaboration with Hansoh ended in 2024 and revenue from an AstraZeneca collaboration decreased. For the first three months of 2026 (Q1 2026), their collaboration revenue was $0.4 million.

A major recent development is the announcement on October 19, 2026, that Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics. This all-cash transaction values Silence Therapeutics at an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion. This acquisition highlights the value of Silence Therapeutics' drug pipeline, particularly its lead candidate, Divesiran, which is in Phase 2 development for a blood disorder called polycythemia vera.

The Metrics That Matter Most

For a clinical-stage biotechnology company like Silence Therapeutics, which is focused on developing new drugs and is not yet consistently profitable, certain financial measures are more important than traditional profit metrics.

1. R&D expenses (Research & Development Expenses): This metric shows how much money the company is pouring into discovering and developing new drugs. For a biotech, R&D is the lifeblood of the business; it's where they invest in their future products. A healthy and consistent investment here is crucial for advancing their drug pipeline. For the full year 2025, Silence Therapeutics spent $67.8 million on R&D. In the second quarter of 2026 (Q2 2026), R&D expenses were $9.1 million.
2. Cash: This tells you how much ready money the company has on hand. Since Silence Therapeutics is not yet profitable and spends heavily on R&D, having enough cash is critical to fund its operations and continue drug development without constantly needing to raise more money, which can dilute existing shareholders. As of June 30, 2026, the company had $72.1 million in cash and cash equivalents.
3. Net income (or Net Loss): This is the company's bottom line – how much money it made or lost after all expenses. For a clinical-stage biotech, it's common to see a net loss as they invest heavily in R&D before any drugs are approved and generate significant sales. Tracking the net loss helps understand their burn rate and how efficiently they are managing their overall costs. For the full year 2025, Silence Therapeutics reported a net loss of $88.6 million. In Q2 2026, the net loss was $12.3 million.
4. Shares outstanding: This number tells you how many shares of the company's stock are currently in the hands of investors. For a biotech, it's important to watch this because companies often issue new shares to raise money for R&D, which can "dilute" the value of existing shares. As of June 30, 2026, Silence Therapeutics had 141,739,180 ordinary shares outstanding.

How to Value This Company

For a clinical-stage biotechnology company like Silence Therapeutics, the P/Book value per share (Price-to-Book value per share) is a relevant valuation metric.

The P/Book value per share compares the company's stock price to its "book value" per share. Book value essentially represents the company's assets (like cash, equipment, and intellectual property) minus its liabilities (what it owes), divided by the number of shares. In simple terms, it's what shareholders would theoretically get if the company sold all its assets, paid off all its debts, and distributed the remaining cash.

For a biotech, the book value often doesn't fully capture the potential future value of its drug pipeline, which is based on scientific innovation and future sales. However, since traditional valuation metrics like Price-to-Earnings (P/E) are often not meaningful for companies with no earnings or negative earnings, P/Book value per share can offer a baseline. A higher P/Book ratio suggests that investors believe the company's future potential (like its promising drug candidates) is worth much more than its current accounting value.

To calculate it, you divide the current stock price by the book value per share. For Silence Therapeutics, with a recent stock price of approximately $19.66 and a book value per share of $0.81, the P/Book value per share would be around 24.27. This high ratio indicates that investors were placing a significant value on the company's future prospects and its drug pipeline, far beyond its current tangible assets, which was ultimately validated by the recent acquisition offer from Merck KGaA.